Advances in Cancer Gene Therapy: New Hope for Malignant Glioma Treatment

Strategic Insights -

Recent research from Japan, Finland, and the United States has made significant strides in the field of cancer gene therapy, particularly in the treatment of malignant gliomas. A study from Kyushu University Hospital found that gene therapy using brain-specific angiogenesis inhibitor 1 (BAI1) showed promising results in inhibiting angiogenesis and tumor growth in human glioblastomas. Another study from the University of Turku demonstrated that a capsid-modified adenovirus efficiently infects tumor endothelial cells, offering a potential solution for targeting tumor vasculature. Finally, researchers at the University of Southern California developed a retargeted gene therapy that blankets malignant glioma without triggering angiogenesis.

Key Takeaways:

  • Gene therapy using BAI1 has been shown to inhibit angiogenesis and tumor growth in human glioblastomas, making it a promising candidate for treatment.
  • The capsid-modified adenovirus Ad5/35 efficiently infects tumor endothelial cells, potentially offering a solution for targeting tumor vasculature.
  • Retargeted gene therapy using basic fibroblast growth factor (FGF2) can increase transgene activity in glioma cells with low or deficient levels of the coxsackievirus B and adenovirus receptor (CAR).
  • This approach suggests that FGF2-retargeting of adenoviral vectors may be a promising approach in glioma gene therapy.
  • Malignant gliomas have varying levels of CAR, alphavbeta3, and alphavbeta5 expression, which affects the efficacy of adenoviral vector-mediated gene delivery.
  • The use of adenoviral vectors in combination with FGF2-retargeting may offer a novel approach for treating malignant gliomas.

Statistics:

  • 100% of human umbilical vein endothelial cells (HUVECs) were infected at a multiplicity of infection (MOI) 120 with Ad5/35.
  • 95% of human aortic endothelial cells (HAECs) were infected at a MOI 3.6 with Ad5/35.
  • 1 to 3 orders of magnitude higher gene expression was observed with Ad5/35 compared to Ad5 in HUVECs and HAECs.

Sources:

  • Kang, X., et al. (2006). Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Therapy, 13(4), 385-392.
  • Shinozaki, K., et al. (2006). Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Therapy, 13(1), 52-59.
  • Wang, W.J., et al. (2005). Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. Journal of Neurosurgery, 103(6), 1058-1066.